Background: Delays in the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) contribute to the significant morbidity of the condition, especially in the era of disease-modifying therapies.
Jonathan Hourmozdi, MD, MSAI, MA +15 more
doaj +1 more source
Analysis of ex vivo ATTR fibrils from patients with systemic ATTR amyloidosis
Transthyretin amyloidosis is a rare and very diverse disease in which amyloid fibrils derived from transthyretin (TTR) deposit within the body. The deposition of amyloid transthyretin (ATTR), usually in the interstitial space between cells, can appear at one or multiple organs, yet mostly the heart is affected.
openaire +1 more source
Cardiorenal Biomarkers and their Implications in Prognosis and Treatment Response of Transthyretin Cardiac Amyloidosis. [PDF]
Jefferson A +5 more
europepmc +1 more source
Machine-learning approach on echocardiography to improve the detection of transthyretin amyloid cardiomyopathy: GRAAL algorithm. [PDF]
Fraix A +15 more
europepmc +1 more source
Multiple Red Flags of Transthyretin Amyloid Cardiomyopathy in a Single Patient: A Case Report on Diagnostic Challenge. [PDF]
Yao L, Chen K, Zhang F, Qin J.
europepmc +1 more source
Cardiac amyloidosis: From diagnosis to therapeutics breakthroughs. [PDF]
Bouziane M, Moufid O, Habbal R.
europepmc +1 more source
Advances in the Diagnosis and Disease-Modifying Management of Transthyretin Amyloid Cardiomyopathy: A Narrative Review. [PDF]
Vijaykumar V.
europepmc +1 more source
Endomyocardial Biopsy Revisited: Diagnostic Value and Expanding Roles in Cardiac Amyloidosis. [PDF]
Schwarting SK, Aus dem Siepen F.
europepmc +1 more source

